Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 251

Sort by

Sort Order Select

Journal Articles

Diagnosis and classification of myelodysplastic syndromes

Robert P Hasserjian, Ulrich Germing, Luca Malcovati

Blood blood.2023020078.

https://doi.org/10.1182/blood.2023020078

Published: 2023

Includes: Supplemental data

Journal Articles

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Blood (2023) 141 (17): 2047–2061.

https://doi.org/10.1182/blood.2022018604

Published: 2023

Includes: Supplemental data

Journal Articles

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1121–1124.

https://doi.org/10.1182/blood-2022-163634

Published: 2022

Journal Articles

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Blood (2022) 140 (Supplement 1): 6976–6978.

https://doi.org/10.1182/blood-2022-158671

Published: 2022

Journal Articles

Validation of a Novel Algorithm with a High Specificity in Ruling out MDS

Felicitas Schulz, Kathrin Nachtkamp, Howard S. Oster, Moshe Mittelman, Norbert Gattermann, Carmen Barthuber, Sarah Schweier, Ulrich Germing

Blood (2022) 140 (Supplement 1): 9789–9790.

https://doi.org/10.1182/blood-2022-163431

Published: 2022

Journal Articles

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Blood (2022) 140 (Supplement 1): 9802–9803.

https://doi.org/10.1182/blood-2022-167716

Published: 2022

Journal Articles

Comparison of Cytomorphology and Histopathology in Myelodysplastic Syndromes (MDS)

Kathrin Nachtkamp, Corinna Strupp, Rosa Faoro, Norbert Gattermann, Ulrich Germing, Stephan E Baldus

Blood (2022) 140 (Supplement 1): 12345–12346.

https://doi.org/10.1182/blood-2022-166172

Published: 2022

Journal Articles

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Maria Sirenko, Elsa Bernard, David B. Beck, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E Arango, Olivier Kosmider, Robert P. Hasserjian, Martin Jadersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Matilde Y Follo, Felicitas R. Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo G. Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio Pires de Souza Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2022) 140 (Supplement 1): 9785–9788.

https://doi.org/10.1182/blood-2022-162397

Published: 2022

Journal Articles

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

Blood (2022) 140 (Supplement 1): 1106–1108.

https://doi.org/10.1182/blood-2022-169050

Published: 2022

Journal Articles

Treatment Patterns and Outcomes in Lower-Risk, Non-Del(5q) Myelodysplastic Syndromes: Findings from a Global Real-World Medical Record Review Study

Maria Diez-Campelo, Aylin Yucel, Ravi K. Goyal, Rohan C. Parikh, Elizabeth Esterberg, Maria Jimenez, Martina Sluga-O'Callaghan, Dimana Miteva, Hong Xiao, Ulrich Germing

Blood (2022) 140 (Supplement 1): 13308–13309.

https://doi.org/10.1182/blood-2022-156411

Published: 2022

Journal Articles

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Blood (2021) 138 (Supplement 1): 2598.

https://doi.org/10.1182/blood-2021-148876

Published: 2021

Journal Articles

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 2606.

https://doi.org/10.1182/blood-2021-146987

Published: 2021

Journal Articles

Real-World Evidence on Treatment Utilization in Lower-Risk Myelodysplastic Syndromes: Findings from a Medical Record Review in the United States

Ulrich Germing, Ravi K. Goyal, Aylin Yucel, Rohan C. Parikh, Maria Jimenez, Martina Sluga-O'Callaghan, Derek Tang, Christina Hughes, Maria Diez-Campelo

Blood (2021) 138 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2021-145576

Published: 2021

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Thomas Schroeder, Matthias Stelljes, Maximilian Christopeit, Eva Schmidt, Christoph Scheid, Jan-Henrik Mikesch, Christina Rautenberg, Paul Jäger, Nadja Drusenheimer, Udo Holtick, Stefan Klein, Rudolf Trenschel, Rainer Haas, Ulrich Germing, Nicolaus Kröger, Guido Kobbe

Blood (2021) 138 (Supplement 1): 411.

https://doi.org/10.1182/blood-2021-153282

Published: 2021

Journal Articles

Increased Bone Marrow Iron at Diagnosis Is Associated with Inferior Prognosis in Patients with Myelodysplastic Syndromes

Annika Kasprzak, Sandra Becker, Martina Rudelius, Corinna Strupp, Kathrin Nachtkamp, Judith Strapatsas, Barbara Hildebrandt, Norbert Gattermann, Ulrich Germing

Blood (2021) 138 (Supplement 1): 3700.

https://doi.org/10.1182/blood-2021-152402

Published: 2021

Journal Articles

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig, Matthias Stelljes, Verena I Gaidzik, Michael Lauseker, Oliver Kriege, Mareike Verbeek, Julia M. Unglaub, Felicitas Thol, Stefan W. Krause, Mathias Haenel, Charlotte Neuerburg, Vladan Vucinic, Christian Jehn, Julia Severmann, Maxi Wass, Lars Fransecky, Jens Chemnitz, Udo Holtick, Kerstin Schäfer-Eckart, Josephine Schröder, Sabrina Kraus, William Hermann Krüger, Ulrich Kaiser, Sebastian Scholl, Lea Henning, Guido Kobbe, Rainer Haas, Nael Alakel, Maximilian Alexander Röhnert, Katja Sockel, Maher Hanoun, Uwe Platzbecker, Tobias A. W. Holderried, Anke Morgner, Michael Heuser, Tim Sauer, Katharina S. Goetze, Eva Maria Wagner, Konstanze Döhner, Hartmut Döhner, Christoph Schliemann, Johannes Schetelig, Martin Bornhäuser, Ulrich Germing, Thomas Schroeder, Moritz Moritz Middeke

Blood (2021) 138 (Supplement 1): 33.

https://doi.org/10.1182/blood-2021-153440

Published: 2021

Journal Articles

Effect of the Neddylation Inhibitor Pevonedistat on Normal Hematopoietic Stem Cell Subsets and Immune Cell Composition

Fatemeh Majidi, Oumaima Stambouli, Ron-Patrick Cadeddu, Simon Kai Brille, Jasmin Ewert, Ulrich Germing, Robert Zeiser, Bernd Giebel, Norbert Gattermann

Blood (2021) 138 (Supplement 1): 4787.

https://doi.org/10.1182/blood-2021-150095

Published: 2021

Journal Articles

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Blood (2021) 138 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2021-146468

Published: 2021

Journal Articles

Severe Anemia Is Associated with a Risk of Infection in Patients with Myelodysplastic Syndromes

Annika Kasprzak, Julia Andresen, Barbara Hildebrandt, Kathrin Nachtkamp, Andrea Kündgen, Guido Kobbe, Norbert Gattermann, Ulrich Germing

Blood (2021) 138 (Supplement 1): 4668.

https://doi.org/10.1182/blood-2021-151288

Published: 2021

Journal Articles

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Blood (2021) 138 (Supplement 1): 4671.

https://doi.org/10.1182/blood-2021-150322

Published: 2021

NARROW

Diagnosis and classification of myelodysplastic syndromes

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Validation of a Novel Algorithm with a High Specificity in Ruling out MDS

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Comparison of Cytomorphology and Histopathology in Myelodysplastic Syndromes (MDS)

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

Treatment Patterns and Outcomes in Lower-Risk, Non-Del(5q) Myelodysplastic Syndromes: Findings from a Global Real-World Medical Record Review Study

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Real-World Evidence on Treatment Utilization in Lower-Risk Myelodysplastic Syndromes: Findings from a Medical Record Review in the United States

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Increased Bone Marrow Iron at Diagnosis Is Associated with Inferior Prognosis in Patients with Myelodysplastic Syndromes

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Effect of the Neddylation Inhibitor Pevonedistat on Normal Hematopoietic Stem Cell Subsets and Immune Cell Composition

Randomized Phase II Study of All- Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

Severe Anemia Is Associated with a Risk of Infection in Patients with Myelodysplastic Syndromes

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only